File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation

TitleTotal and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation
Authors
KeywordsHematopoietic stem cell transplantation
Pediatrics
Thymoglobulin
Pharmacokinetics
Graft-versus-host disease (GVHD)
Rabbit antithymocyte globulin (rATG)
Bone marrow transplantation
Issue Date2009
Citation
Biology of Blood and Marrow Transplantation, 2009, v. 15, n. 2, p. 274-278 How to Cite?
AbstractRabbit antithymocyte globulin (rATG; Thymoglobulin®) is currently used to prevent or treat graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation (HSCT). The dose and schedule of rATG as part of the preparative regimen for unrelated donor (URD) bone marrow transplantation (BMT) have not been optimized in pediatric patients. We conducted a prospective study of 13 pediatric patients with hematologic malignancies undergoing URD BMT at St. Jude Children's Research Hospital from October 2003 to March 2005, to determine the pharmacokinetics and toxicities of active and total rATG. The conditioning regimen comprised total body irradiation (TBI), thiotepa, and cyclophosphamide (Cy); cyclosporine (CsA) and methotrexate (MTX) were administered as GVHD prophylaxis. Patients received a total dose of 10 mg/kg rATG, and serial blood samples were assayed for total rATG by enzyme linked immunosorbent assay (ELISA) and active rATG by florescein activated cell sorting (FACS). We found that our weight-based dosing regimen for rATG was effective and well tolerated by patients. The half-lives of total and active rATG were comparable to those from previous studies, and despite high doses our patients had low maximum concentrations of active and total rATG. There were no occurrences of grade iii-iv GVHD even in patients having low peak rATG levels, and the overall incidence of grade II GVHD was only 15%. None of the patients had serious infections following transplantation. These data support the use of a 10 mg/kg dose of rATG in children with hematologic malignancies because it can be administered without increasing the risk of graft rejection, or serious infection in pediatric patients with a low rate of GVHD. These conclusions may not apply to patients with nonmalignant disorders. © 2009 American Society for Blood and Marrow Transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/294425
ISSN
2022 Impact Factor: 4.3
2020 SCImago Journal Rankings: 2.301
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCall, Sandra K.-
dc.contributor.authorKasow, Kimberly A.-
dc.contributor.authorBarfield, Raymond-
dc.contributor.authorMadden, Renee-
dc.contributor.authorLeung, Wing-
dc.contributor.authorHorwitz, Edwin-
dc.contributor.authorWoodard, Paul-
dc.contributor.authorPanetta, John C.-
dc.contributor.authorBaker, Sharyn-
dc.contributor.authorHandgretinger, Rupert-
dc.contributor.authorRodman, John-
dc.contributor.authorHale, Gregory A.-
dc.date.accessioned2020-12-03T08:22:42Z-
dc.date.available2020-12-03T08:22:42Z-
dc.date.issued2009-
dc.identifier.citationBiology of Blood and Marrow Transplantation, 2009, v. 15, n. 2, p. 274-278-
dc.identifier.issn1083-8791-
dc.identifier.urihttp://hdl.handle.net/10722/294425-
dc.description.abstractRabbit antithymocyte globulin (rATG; Thymoglobulin®) is currently used to prevent or treat graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation (HSCT). The dose and schedule of rATG as part of the preparative regimen for unrelated donor (URD) bone marrow transplantation (BMT) have not been optimized in pediatric patients. We conducted a prospective study of 13 pediatric patients with hematologic malignancies undergoing URD BMT at St. Jude Children's Research Hospital from October 2003 to March 2005, to determine the pharmacokinetics and toxicities of active and total rATG. The conditioning regimen comprised total body irradiation (TBI), thiotepa, and cyclophosphamide (Cy); cyclosporine (CsA) and methotrexate (MTX) were administered as GVHD prophylaxis. Patients received a total dose of 10 mg/kg rATG, and serial blood samples were assayed for total rATG by enzyme linked immunosorbent assay (ELISA) and active rATG by florescein activated cell sorting (FACS). We found that our weight-based dosing regimen for rATG was effective and well tolerated by patients. The half-lives of total and active rATG were comparable to those from previous studies, and despite high doses our patients had low maximum concentrations of active and total rATG. There were no occurrences of grade iii-iv GVHD even in patients having low peak rATG levels, and the overall incidence of grade II GVHD was only 15%. None of the patients had serious infections following transplantation. These data support the use of a 10 mg/kg dose of rATG in children with hematologic malignancies because it can be administered without increasing the risk of graft rejection, or serious infection in pediatric patients with a low rate of GVHD. These conclusions may not apply to patients with nonmalignant disorders. © 2009 American Society for Blood and Marrow Transplantation.-
dc.languageeng-
dc.relation.ispartofBiology of Blood and Marrow Transplantation-
dc.subjectHematopoietic stem cell transplantation-
dc.subjectPediatrics-
dc.subjectThymoglobulin-
dc.subjectPharmacokinetics-
dc.subjectGraft-versus-host disease (GVHD)-
dc.subjectRabbit antithymocyte globulin (rATG)-
dc.subjectBone marrow transplantation-
dc.titleTotal and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.bbmt.2008.11.027-
dc.identifier.pmid19167688-
dc.identifier.pmcidPMC4776329-
dc.identifier.scopuseid_2-s2.0-58249138311-
dc.identifier.volume15-
dc.identifier.issue2-
dc.identifier.spage274-
dc.identifier.epage278-
dc.identifier.eissn1523-6536-
dc.identifier.isiWOS:000263016600014-
dc.identifier.issnl1083-8791-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats